Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a newly diagnosed GBM (Cohort 2); mirdametinib alone in other NF1-associated High-Grade Gliomas (Cohort 3).

NCT Number	NCT07521657
Lead Sponsor	University of Alabama at Birmingham Collaborators: Children's Hospital of Philadelphia, Congressionally Directed Medical Research Programs
Conditions	Neurofibromatosis 1 (NF1)
Enrollment	55 participants
Start Date	2026-08-01
Primary Completion	2030-08-01 (estimated)
Study Completion	2031-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-13